{"doi":"10.21873/anticanres.14478","title":"Changes in Immunological Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemoimmunotherapy","abstract":null,"journal":"Anticancer Research","year":2020,"id":598851,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1534746,"name":"YOICHIRO YOSHIDA","orcid":null,"position":1,"is_corresponding":false},{"id":1534748,"name":"TOSHIKI MAEDA","orcid":null,"position":2,"is_corresponding":false},{"id":1534750,"name":"GUMPEI YOSHIMATSU","orcid":null,"position":3,"is_corresponding":false},{"id":1534752,"name":"NAOYA AISU","orcid":null,"position":4,"is_corresponding":false},{"id":1534755,"name":"KANEFUMI YAMASHITA","orcid":null,"position":5,"is_corresponding":false},{"id":1534756,"name":"AKIRA KOMONO","orcid":null,"position":6,"is_corresponding":false},{"id":1534757,"name":"RYUJI KAJITANI","orcid":null,"position":7,"is_corresponding":false},{"id":1534758,"name":"YOSHIKO MATSUMOTO","orcid":null,"position":8,"is_corresponding":false},{"id":1534759,"name":"HIDEKI NAGANO","orcid":null,"position":9,"is_corresponding":false},{"id":1534760,"name":"KEIKO NAITO","orcid":null,"position":10,"is_corresponding":false},{"id":1534761,"name":"KOSEI YASUMOTO","orcid":null,"position":11,"is_corresponding":false},{"id":1534762,"name":"RISHU TAKIMOTO","orcid":null,"position":12,"is_corresponding":false},{"id":1534763,"name":"TAKASHI KAMIGAKI","orcid":null,"position":13,"is_corresponding":false},{"id":1534764,"name":"SHIGENORI GOTO","orcid":null,"position":14,"is_corresponding":false},{"id":1534765,"name":"FUMIHIRO YOSHIMURA","orcid":null,"position":15,"is_corresponding":false},{"id":1534768,"name":"NAOAKI SAKATA","orcid":null,"position":16,"is_corresponding":false},{"id":1534770,"name":"SHOHTA KODAMA","orcid":null,"position":17,"is_corresponding":false},{"id":1534772,"name":"SUGURU HASEGAWA","orcid":null,"position":18,"is_corresponding":false},{"id":1534743,"name":"TEPPEI YAMADA","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Changes in Immunological Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemoimmunotherapy","abstract":"BACKGROUND/AIM: Chemoimmunotherapy is a promising treatment for various malignant diseases. In this study, we examined whether first-line chemoimmunotherapy using adoptive immune-cell therapy was effective for metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: The therapeutic efficacy and safety of the standard first-line chemoimmunotherapy with adoptive αβ T cell therapy and bevacizumab were assessed using thirty-two patients with mCRC in our hospital. Immunological status after this chemoimmunotherapy was also evaluated. RESULTS: The response and disease control rates were 68.8% and 87.5%, respectively. Further, median progression-free and overall survival were 14.2 and 35.3 months. Immunotherapy-associated toxicity was minimal. Significant decrease in the change of monocyte number (p=0.006) and increase in the change of rate of lymphocyte-to-monocyte ratio (p=0.039) were seen in the complete response group. CONCLUSION: First-line chemoimmunotherapy with adoptive αβ T cell therapy may be useful for mCRC.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"32727803","pmcid":null,"openalex_id":"https://openalex.org/W3046481156","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.10779858,"influential_citations":0,"citation_trend":[],"oa_status":"bronze","license":null,"oa_locations":[{"url":"https://ar.iiarjournals.org/content/anticanres/40/8/4763.full.pdf","host_type":"journal"},{"url":"https://ar.iiarjournals.org/content/anticanres/40/8/4763.full.pdf","host_type":"publisher"},{"url":"https://syndication.highwire.org/content/doi/10.21873/anticanres.14478","host_type":"publisher"},{"url":"https://doi.org/10.21873/anticanres.14478","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/32727803","host_type":"repository"}],"fields_of_study":["CAR-T cell therapy research","Immunotherapy and Immune Responses","Cancer Immunotherapy and Biomarkers"],"mesh_terms":["Bevacizumab","Progression-Free Survival","Adult","Aged","Aged, 80 and over","Antineoplastic Combined Chemotherapy Protocols","Female","Fluorouracil","Humans","Immunotherapy","Lymphocytes","Male","Middle Aged","Monocytes","Colorectal Neoplasms"],"keywords":["Chemoimmunotherapy","Medicine","Oncology","Colorectal cancer","Internal medicine","Immunotherapy","Cancer","Bevacizumab","Immunology","Chemotherapy","Immunological Status","Αβ T Cell Therapy"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-28T16:19:47.030657Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}